Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker study in moderate to severe ulcerative colitis treated with targeted therapies
NL-OMON52173Completed
- Sponsor
- Innovative Medicines Initiative
- Start
- Jan 2022
- Countries
- 1
01
Overview
Open-label trial in autoimmune colitis (4 cohorts), sponsored by Innovative Medicines Initiative. Primary endpoints: Remission at week 14 and Clinical response at week 14. Started Jan 2022; status: completed.
02
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON52173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52173.